Rhythm Pharmaceuticals (NASDAQ:RYTM) Upgraded at Royal Bank Of Canada

Royal Bank Of Canada upgraded shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) to a moderate buy rating in a research report sent to investors on Wednesday morning,Zacks.com reports.

A number of other research analysts have also issued reports on the stock. HC Wainwright upped their target price on shares of Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. Oppenheimer cut shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 5th. UBS Group reissued a “buy” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, December 17th. Canaccord Genuity Group raised their price target on Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Finally, Guggenheim increased their price objective on Rhythm Pharmaceuticals from $120.00 to $140.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $131.50.

Rhythm Pharmaceuticals Trading Down 3.3%

Shares of RYTM stock opened at $99.78 on Wednesday. The stock has a 50 day simple moving average of $105.41 and a 200-day simple moving average of $103.30. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20. The company has a market cap of $6.66 billion, a price-to-earnings ratio of -32.19 and a beta of 2.00.

Insider Transactions at Rhythm Pharmaceuticals

In other news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the sale, the chief financial officer directly owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the sale, the insider owned 20,814 shares in the company, valued at $2,310,354. This represents a 13.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 25,003 shares of company stock valued at $2,589,015 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of RYTM. Xponance LLC raised its stake in Rhythm Pharmaceuticals by 2.6% in the fourth quarter. Xponance LLC now owns 4,269 shares of the company’s stock valued at $457,000 after purchasing an additional 107 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Rhythm Pharmaceuticals by 4.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after buying an additional 110 shares during the period. Smartleaf Asset Management LLC boosted its position in Rhythm Pharmaceuticals by 39.5% in the fourth quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock worth $43,000 after purchasing an additional 113 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Rhythm Pharmaceuticals by 0.7% in the second quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock worth $1,104,000 after buying an additional 114 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after buying an additional 118 shares during the period.

Rhythm Pharmaceuticals News Summary

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: RBC/ Royal Bank initiated coverage and/or upgraded RYTM with an outperform/moderate-buy stance, bringing renewed institutional attention and a formal buy-style endorsement that can support near-term demand. RBC initiates coverage
• Positive Sentiment: Several sell-side firms have raised price targets and reiterated buy/overweight ratings (Wells Fargo, Morgan Stanley, Citizens/JMP, UBS, TD Cowen), reinforcing a bullish consensus and higher upside expectations. MarketBeat analyst roundup
• Positive Sentiment: Operational narrative improving: a Yahoo Finance piece highlights Imcivree revenue ramp and updated management targets — if execution continues, this supports medium-term revenue growth that underpins analyst optimism. Imcivree revenue and targets
• Neutral Sentiment: Zacks moved coverage from “strong sell” to “hold” and flagged RYTM as positioned to potentially beat upcoming earnings — these are watchpoints that reduce perceived downside but are not immediate catalysts without reported results. Zacks coverage and earnings outlook
• Negative Sentiment: Insider selling by CFO Hunter C. Smith: filings show sales of several thousand shares (transactions reported for Feb. 17 and Feb. 19 at ~ $101 per share). While the amounts are a small percentage of his total holding, such sales can trigger near-term selling pressure or investor concern about insider conviction. CFO sale disclosure

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.